# A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

> **NCT00002377** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Cytomegalovirus Retinitis
- HIV Infections

## Interventions

- **DRUG:** Valganciclovir
- **DRUG:** Ganciclovir

## Key facts

- **NCT ID:** NCT00002377
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-01
- **Primary completion:** 2002-12
- **Final completion:** 2002-12
- **Target enrollment:** — (—)
- **Last updated:** 2017-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002377, "A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*